Drug class
Migraine Prevention Medications
Migraine prevention medications encompass a heterogeneous functional class of pharmacologic agents administered on an ongoing schedule to decrease the frequency, severity, and duration of migraine attacks rather than abort acute headache episodes. Read more about Migraine Prevention Medications
9 drugs in this class 7 manufacturers
Drugs in Migraine Prevention Medications
AJOVY (fremanezumab-vfrm)
EMGALITY PEN (galcanezumab-gnlm)
VYEPTI (eptinezumab-jjmr)
NURTEC ODT (rimegepant sulfate)
AJOVY AUTOINJECTOR (fremanezumab-vfrm)
AJOVY SYRINGE (fremanezumab-vfrm)
QULIPTA (atogepant)
NURTEC ODT (rimegepant sulfate)
Migraine prevention medications encompass a heterogeneous functional class of pharmacologic agents administered on an ongoing schedule to decrease the frequency, severity, and duration of migraine attacks rather than abort acute headache episodes.
Because this grouping represents a broad clinical indication rather than a single chemical entity or single mechanism of action, it spans multiple drug families.
These include migraine-specific therapies—such as calcitonin gene-related peptide (CGRP) receptor antagonists and monoclonal antibodies—as well as conventional non-specific agents like beta-blockers, anticonvulsants, tricyclic antidepressants, and neurotoxins.
Collectively, their therapeutic role centers on modulating central and peripheral neurovascular pathways, inhibiting cortical hyperexcitability, or blocking nociceptive neuropeptide transmission.
These agents are primarily indicated for the management and prophylaxis of episodic migraine and chronic migraine.
-
fda.gov
Migraine prevention medications encompass a heterogeneous functional class of pharmacologic agents administered on an ongoing schedule to decrease the frequency, severity, and duration of migraine attacks rather than abort acute headache episodes
-
americanmigrainefoundation.org
Migraine prevention medications encompass a heterogeneous functional class of pharmacologic agents administered on an ongoing schedule to decrease the frequency, severity, and duration of migraine attacks rather than abort acute headache episodes Because this grouping represents a broad clinical indication rather than a single chemical entity or single mechanism of action, it spans multiple drug families These include migraine-specific therapies—such as calcitonin gene-related peptide (CGRP) rec...
-
neurologylive.com
Because this grouping represents a broad clinical indication rather than a single chemical entity or single mechanism of action, it spans multiple drug families These agents are primarily indicated for the management and prophylaxis of episodic migraine and chronic migraine
-
nih.gov
These include migraine-specific therapies—such as calcitonin gene-related peptide (CGRP) receptor antagonists and monoclonal antibodies—as well as conventional non-specific agents like beta-blockers, anticonvulsants, tricyclic antidepressants, and neurotoxins
-
medpagetoday.com
Collectively, their therapeutic role centers on modulating central and peripheral neurovascular pathways, inhibiting cortical hyperexcitability, or blocking nociceptive neuropeptide transmission
-
fda.gov
These agents are primarily indicated for the management and prophylaxis of episodic migraine and chronic migraine
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.